Recent Updates — TKPHF

Takeda Pharmaceutical reported a six-month net profit attributable to owners of the Company of JPY 305.6 billion (USD approx. $2.04 billion), a 171.8% increase from the prior year period, driven by foreign exchange tailwinds and significantly lower amortization and impairment losses. Revenue rose 8.4% to JPY 2,407.0 billion, with operating profit surging 60.4% to JPY 406.7 billion. The company also redeemed USD 1,500 million of senior notes during the period. Takeda is a global pharmaceutical company focused on gastroenterology, oncology, neuroscience, and rare diseases.

Takeda Pharmaceutical reported a 171.6% surge in first-half net profit to JPY 305.7 billion for the period ended September 30, 2026, driven by a significant decline in amortization and impairment losses on intangible assets. Revenue increased 8.4% to JPY 2,407.0 billion, though constant exchange rate revenue declined slightly due to loss of exclusivity impacts offsetting growth in key brands like ENTYVIO and ADCETRIS. Operating profit rose 60.4% to JPY 406.7 billion. The company also revised its full-year management guidance downward, projecting a low-single digit decline in Core Revenue and a low-teens percent drop in Core EPS for the fiscal year ending March 31, 2027. Takeda Pharmaceutical Company Limited is a global pharmaceutical company focused on prescription medicines, vaccines, and plasma-derived therapies.

Takeda completed the issuance of 10,780,950 new shares and disposal of 6,096,159 treasury shares on July 8, 2026, under its Long-Term Incentive Plan for employees outside of Japan. The total number of shares issued and disposed of was 16,877,109 ordinary shares at a price of 5,050 yen per share, totaling 85,229,400,450 yen. The change from the original plan was due to partial forfeiture of rights by allottees. Takeda is a biopharmaceutical company focused on life-transforming treatments in therapeutic areas such as oncology, neuroscience, and rare diseases.